Home/Nanobiotix/Anne-Sophie Larivière
AL

Anne-Sophie Larivière

Vice President, Strategy & Operational Excellence

Nanobiotix

Therapeutic Areas

Nanobiotix Pipeline

DrugIndicationPhase
NBTXR3Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)Phase III
NBTXR3 + anti-PD-1Solid TumorsPhase I
Curadigm Platform ProgramsUndisclosedDiscovery/Preclinical